Asociación entre valsartán e inhibidores de neprilisina en el manejo de la falla cardiaca.

Autores:: Boneu Yepez, Deiby
Barragán Montiel, Robinson
Arroyo Carrascal, Dayana

Tipo de recurso:: Article of journal

Fecha de publicación:: 2021

Institución:: Universidad de Cartagena

Repositorio:: Repositorio Universidad de Cartagena

Idioma:: spa

id	UCART2_e5f6c563d5acfdf26a0aa354d50dec23
oai_identifier_str	oai:repositorio.unicartagena.edu.co:11227/13491
network_acronym_str	UCART2
network_name_str	Repositorio Universidad de Cartagena
repository_id_str
dc.title.spa.fl_str_mv	Asociación entre valsartán e inhibidores de neprilisina en el manejo de la falla cardiaca.
dc.title.translated.eng.fl_str_mv	Association between valsartan and neprilisin inhibitors in the management of heart failure.
title	Asociación entre valsartán e inhibidores de neprilisina en el manejo de la falla cardiaca.
spellingShingle	Asociación entre valsartán e inhibidores de neprilisina en el manejo de la falla cardiaca. Heart failure Valsartan Neprilysin Atrial natriuretic factor Angiotensin-converting enzyme inhibitors Insuficiencia Cardíaca Valsartán Neprilisina Péptido natriurético atrial Inhibidores de la enzima convertidora de angiotensina
title_short	Asociación entre valsartán e inhibidores de neprilisina en el manejo de la falla cardiaca.
title_full	Asociación entre valsartán e inhibidores de neprilisina en el manejo de la falla cardiaca.
title_fullStr	Asociación entre valsartán e inhibidores de neprilisina en el manejo de la falla cardiaca.
title_full_unstemmed	Asociación entre valsartán e inhibidores de neprilisina en el manejo de la falla cardiaca.
title_sort	Asociación entre valsartán e inhibidores de neprilisina en el manejo de la falla cardiaca.
dc.creator.fl_str_mv	Boneu Yepez, Deiby Barragán Montiel, Robinson Arroyo Carrascal, Dayana
dc.contributor.author.spa.fl_str_mv	Boneu Yepez, Deiby Barragán Montiel, Robinson Arroyo Carrascal, Dayana
dc.subject.eng.fl_str_mv	Heart failure Valsartan Neprilysin Atrial natriuretic factor Angiotensin-converting enzyme inhibitors
topic	Heart failure Valsartan Neprilysin Atrial natriuretic factor Angiotensin-converting enzyme inhibitors Insuficiencia Cardíaca Valsartán Neprilisina Péptido natriurético atrial Inhibidores de la enzima convertidora de angiotensina
dc.subject.spa.fl_str_mv	Insuficiencia Cardíaca Valsartán Neprilisina Péptido natriurético atrial Inhibidores de la enzima convertidora de angiotensina
publishDate	2021
dc.date.accessioned.none.fl_str_mv	2021-07-15 00:00:00
dc.date.available.none.fl_str_mv	2021-07-15 00:00:00
dc.date.issued.none.fl_str_mv	2021-07-15
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_dcae04bc http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv	Text
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.local.eng.fl_str_mv	Journal article
dc.type.redcol.spa.fl_str_mv	http://purl.org/redcol/resource_type/ARTREV
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.issn.none.fl_str_mv	2215-7840
dc.identifier.doi.none.fl_str_mv	10.32997/rcb-2021-3500
dc.identifier.eissn.none.fl_str_mv	2389-7252
dc.identifier.url.none.fl_str_mv	https://doi.org/10.32997/rcb-2021-3500
identifier_str_mv	2215-7840 10.32997/rcb-2021-3500 2389-7252
url	https://doi.org/10.32997/rcb-2021-3500
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Ciencias Biomédicas
dc.relation.bitstream.none.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/3500/2949
dc.relation.citationedition.spa.fl_str_mv	Núm. 3 , Año 2021
dc.relation.citationendpage.none.fl_str_mv	206
dc.relation.citationissue.spa.fl_str_mv	3
dc.relation.citationstartpage.none.fl_str_mv	198
dc.relation.citationvolume.spa.fl_str_mv	10
dc.relation.references.spa.fl_str_mv	Ulate-Montero G, Ulate-Campos A, Actualización en los mecanismos fisiopatológicos de la insuficiencia cardiaca, AMC, Vol 50 (1), enero-marzo 2008. De La Serna F, Insuficiencia Cardíaca Crónica, Editorial Federación Argentina de Cardiología, 3ra. Edición 2010, Capitulo 4, 2010. De La Serna F, Insuficiencia Cardíaca Crónica, Editorial Federación Argentina de Cardiología, 3ra. Edición 2010, capitulo 3, actualizado en 2015. Jagdeep SS Singh, Chim C Lang, Angiotensin receptor-neprilysin Inhibitors Angiotensin receptor- neprilysin inhibitors, V ascular Health and Risk Management 2015: 11 283–295. Dickstein K, Cohen-Solal A, Filippatos A. Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008), Rev Esp Cardiol. 2008; 61(12): 1329.e1-1329.e70. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990‐2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1789–1858. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020; 22(8): 1342-1356. Jaramillo C, et al., Consenso Colombiano para el diagnóstico y tratamiento de la insuficiencia cardiaca crónica, sociedad colombiana de cardiología y cirugía cardiovascular, 1 edición, inversiones tecnograficas S.A.S., Bogotá, noviembre de 2014. Tousignant M, Mbuila Mampuya W, Telerehabilitation for patients with heart failure, Cardiovasc Diagn Ther 2015; 5(1): 74-78. Piotr Ponikowski, Adriaan A. Voors, Stefan D. Anker et al, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, European Heart Journal June 8, 2016. Song W, Wang H, Wu Q. Atrial Natriuretic Peptide in Cardiovascular Biology and Disease (NPPA). Gene. 2015; 569(1): 1-6. Jagdeep SS Singh, Chim C Lang, Angiotensin receptor-neprilysin Inhibitors Angiotensin receptor- neprilysin inhibitors, V ascular Health and Risk Management 2015: 11 283–295. Barrett AJ, Rawlings ND, O’Brien EA. The MEROPS database as a protease information system. J Struct Biol 2001;1 34: 95–102. Nalivaeva, N. N., Zhuravin, I. A., & Turner, A. J. (2020). Neprilysin expression and functions in development, ageing and disease. Mechanisms of ageing and development, 192, 111363. https://doi.org/10.1016/j.mad.2020.111363 Salazar, J., Rojas-Quintero, J., Cano, C., Pérez, J. L., Ramírez, P., Carrasquero, R., Torres, W., Espinoza, C., Chacín-González, M., & Bermúdez, V . (2020). Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?. Current cardiology reviews, 16(1), 25–35. https://doi.org/10.2174/1573403X15666190625160352 Chaves G, Diaztagle J, Vargas V, Mejía M, Sprockel J, Hernández J, Cumplimiento de guías en pacientes hospitalizados con falla cardiaca ¿Cómo estamos? Acta Médica Colombiana 2014, 39 (Enero-Marzo). Von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther 144(1): 41–49 (2014). García S, Parodi R, Tos y angioedema en pacientes tratados con inhibidores de la enzima convertidora de la angiotensina siempre es culpable la medicación, Rev. argent. cardiol. vol.79 no.2 Ciudad Autónoma de Buenos Aires mar./abr. 2011. Braunwald E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol. 2015; 65: 1029–1041. Grothusen A, Divchev D, Luchtefeld M, Schieffer B. Angiotensin II type 1 receptor blockade: high hopes sent back to reality? Minerva Cardioangiol. 2009 Dec; 57(6): 773-85. Forrester, S. J., Booz, G. W., Sigmund, C. D., Coffman, T. M., Kawai, T., Rizzo, V., Scalia, R., & Eguchi, S. (2018). Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. Physiological reviews, 98(3), 1627– 1738. https://doi.org/10.1152/physrev.00038.2017 Kinoshita H, Kuwahara K, Nishida M, Jian Z, Rong X, Kiyonaka S, Kuwabara Y, Kurose H, Inoue R, Mori Y, Li Y, Nakagawa Y, Usami S, Fujiwara M, Yamada Y, Minami T, Ueshima K, Nakao K. Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-Asignaling in the heart. Circ Res. 2010 Jun 25; 106(12): 1849-60. Gaggin H.K., Januzzi J.L. Jr. (2013) Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 1832: 2442–2450. Giuseppe Lippi, Fabian Sanchis-Gomar, Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge, International Journal of Cardiology 219 (2016) 111–114. Pacheco-Quinto J,Herdt A,Eckman CB,Eckman EA. Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease. J Alzheimers Dis. 2013; 33 Suppl 1: S101-10. Galli A, Lombardi F, Neprilysin Inhibition for Heart Failure, The new england journal of medicine, nengljmed 371;24 nejm.org december 11, 2014. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11; 371(11): 993-1004. to S, Satoh M, Tamaki Y., Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction, The Japanese Society of Hypertension, Hypertension Research (2015) 38, 269–275. Adriaan A. Voors et al, Renal effects of neprilysin inhibitor LCZ696 in patients with HFpEF, European Journal of Heart Failure © 2015 European Society of Cardiology, European Journal of Heart Failure (2015) 17, 510–517. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin- converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013; 15: 1062–1073. Sadayoshi Ito et al, Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction, Hypertension Research (2015) 38, 269–275. Dalzell JR, Seed A, Berry C, Whelan CJ, Petrie MC, Padmanabhan N, Clarke A, Biggerstaff F, Hillier C, McMurray JJ. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. Cardiovasc Ther. 2014 Feb; 32(1): 13-8. Jagdeep SS Singh, Chim C Lang, Angiotensin receptor-neprilysin Inhibitors Angiotensin receptor- neprilysin inhibitors, V ascular Health and Risk Management 2015:11 283–295. Akshay S. Desai et al, Influence of Sacubitril Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization, JACC VOL. 68, NO.3, 2016, JULY 19, 2016: 241–8. Dargad RR, Prajapati MR, Dargad RR, Parekh JD. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.Indian Heart J. 2018; 70 Suppl 1(Suppl 1): S102-S110. Ganesananthan S, Shah N, Shah P, et al. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study. Open Heart. 2020; 7(2): e001305. Writing Committee, Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Jan 4: S0735-1097 (20) 37867-0. Wachter R, Senni M, Belohlavek J, et al. TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019 Aug; 21(8): 998-1007. Senni M, McMurray JJ, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016 Sep; 18(9): 1193-202.
dc.rights.spa.fl_str_mv	Deiby Boneu Yepez, Robinson Barragán Montiel, Dayana Arroyo Carrascal - 2021
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Deiby Boneu Yepez, Robinson Barragán Montiel, Dayana Arroyo Carrascal - 2021 https://creativecommons.org/licenses/by-nc-sa/4.0 http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Universidad de Cartagena
dc.source.spa.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3500
institution	Universidad de Cartagena
bitstream.url.fl_str_mv	https://repositorio.unicartagena.edu.co/bitstreams/3793f95a-21ff-4137-8fb5-f21daef45a5a/download
bitstream.checksum.fl_str_mv	d57484b0c8f732abff7b01919e4ce92a
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Biblioteca Digital Universidad de Cartagena
repository.mail.fl_str_mv	bdigital@metabiblioteca.com
_version_	1814213992299626496
spelling	Boneu Yepez, DeibyBarragán Montiel, RobinsonArroyo Carrascal, Dayana2021-07-15 00:00:002021-07-15 00:00:002021-07-152215-784010.32997/rcb-2021-35002389-7252https://doi.org/10.32997/rcb-2021-3500application/pdfspaUniversidad de CartagenaRevista Ciencias Biomédicashttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/3500/2949Núm. 3 , Año 2021206319810Ulate-Montero G, Ulate-Campos A, Actualización en los mecanismos fisiopatológicos de la insuficiencia cardiaca, AMC, Vol 50 (1), enero-marzo 2008.De La Serna F, Insuficiencia Cardíaca Crónica, Editorial Federación Argentina de Cardiología, 3ra. Edición 2010, Capitulo 4, 2010.De La Serna F, Insuficiencia Cardíaca Crónica, Editorial Federación Argentina de Cardiología, 3ra. Edición 2010, capitulo 3, actualizado en 2015.Jagdeep SS Singh, Chim C Lang, Angiotensin receptor-neprilysin Inhibitors Angiotensin receptor- neprilysin inhibitors, V ascular Health and Risk Management 2015: 11 283–295.Dickstein K, Cohen-Solal A, Filippatos A. Guía de práctica clínica de la Sociedad Europea de Cardiología (ESC) para el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica (2008), Rev Esp Cardiol. 2008; 61(12): 1329.e1-1329.e70.GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990‐2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018; 392: 1789–1858.Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020; 22(8): 1342-1356.Jaramillo C, et al., Consenso Colombiano para el diagnóstico y tratamiento de la insuficiencia cardiaca crónica, sociedad colombiana de cardiología y cirugía cardiovascular, 1 edición, inversiones tecnograficas S.A.S., Bogotá, noviembre de 2014.Tousignant M, Mbuila Mampuya W, Telerehabilitation for patients with heart failure, Cardiovasc Diagn Ther 2015; 5(1): 74-78.Piotr Ponikowski, Adriaan A. Voors, Stefan D. Anker et al, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure, European Heart Journal June 8, 2016.Song W, Wang H, Wu Q. Atrial Natriuretic Peptide in Cardiovascular Biology and Disease (NPPA). Gene. 2015; 569(1): 1-6.Jagdeep SS Singh, Chim C Lang, Angiotensin receptor-neprilysin Inhibitors Angiotensin receptor- neprilysin inhibitors, V ascular Health and Risk Management 2015: 11 283–295.Barrett AJ, Rawlings ND, O’Brien EA. The MEROPS database as a protease information system. J Struct Biol 2001;1 34: 95–102.Nalivaeva, N. N., Zhuravin, I. A., & Turner, A. J. (2020). Neprilysin expression and functions in development, ageing and disease. Mechanisms of ageing and development, 192, 111363. https://doi.org/10.1016/j.mad.2020.111363Salazar, J., Rojas-Quintero, J., Cano, C., Pérez, J. L., Ramírez, P., Carrasquero, R., Torres, W., Espinoza, C., Chacín-González, M., & Bermúdez, V . (2020). Neprilysin: A Potential Therapeutic Target of Arterial Hypertension?. Current cardiology reviews, 16(1), 25–35. https://doi.org/10.2174/1573403X15666190625160352Chaves G, Diaztagle J, Vargas V, Mejía M, Sprockel J, Hernández J, Cumplimiento de guías en pacientes hospitalizados con falla cardiaca ¿Cómo estamos? Acta Médica Colombiana 2014, 39 (Enero-Marzo).Von Lueder TG, Atar D, Krum H. Current role of neprilysin inhibitors in hypertension and heart failure. Pharmacol Ther 144(1): 41–49 (2014).García S, Parodi R, Tos y angioedema en pacientes tratados con inhibidores de la enzima convertidora de la angiotensina siempre es culpable la medicación, Rev. argent. cardiol. vol.79 no.2 Ciudad Autónoma de Buenos Aires mar./abr. 2011.Braunwald E. The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure. J Am Coll Cardiol. 2015; 65: 1029–1041.Grothusen A, Divchev D, Luchtefeld M, Schieffer B. Angiotensin II type 1 receptor blockade: high hopes sent back to reality? Minerva Cardioangiol. 2009 Dec; 57(6): 773-85.Forrester, S. J., Booz, G. W., Sigmund, C. D., Coffman, T. M., Kawai, T., Rizzo, V., Scalia, R., & Eguchi, S. (2018). Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology. Physiological reviews, 98(3), 1627– 1738. https://doi.org/10.1152/physrev.00038.2017Kinoshita H, Kuwahara K, Nishida M, Jian Z, Rong X, Kiyonaka S, Kuwabara Y, Kurose H, Inoue R, Mori Y, Li Y, Nakagawa Y, Usami S, Fujiwara M, Yamada Y, Minami T, Ueshima K, Nakao K. Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-Asignaling in the heart. Circ Res. 2010 Jun 25; 106(12): 1849-60.Gaggin H.K., Januzzi J.L. Jr. (2013) Biomarkers and diagnostics in heart failure. Biochim Biophys Acta 1832: 2442–2450.Giuseppe Lippi, Fabian Sanchis-Gomar, Monitoring B-type natriuretic peptide in patients undergoing therapy with neprilysin inhibitors. An emerging challenge, International Journal of Cardiology 219 (2016) 111–114.Pacheco-Quinto J,Herdt A,Eckman CB,Eckman EA. Endothelin-converting enzymes and related metalloproteases in Alzheimer's disease. J Alzheimers Dis. 2013; 33 Suppl 1: S101-10.Galli A, Lombardi F, Neprilysin Inhibition for Heart Failure, The new england journal of medicine, nengljmed 371;24 nejm.org december 11, 2014.McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014 Sep 11; 371(11): 993-1004.to S, Satoh M, Tamaki Y., Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction, The Japanese Society of Hypertension, Hypertension Research (2015) 38, 269–275.Adriaan A. Voors et al, Renal effects of neprilysin inhibitor LCZ696 in patients with HFpEF, European Journal of Heart Failure © 2015 European Society of Cardiology, European Journal of Heart Failure (2015) 17, 510–517.McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin- converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013; 15: 1062–1073.Sadayoshi Ito et al, Safety and efficacy of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Japanese patients with hypertension and renal dysfunction, Hypertension Research (2015) 38, 269–275.Dalzell JR, Seed A, Berry C, Whelan CJ, Petrie MC, Padmanabhan N, Clarke A, Biggerstaff F, Hillier C, McMurray JJ. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat. Cardiovasc Ther. 2014 Feb; 32(1): 13-8.Jagdeep SS Singh, Chim C Lang, Angiotensin receptor-neprilysin Inhibitors Angiotensin receptor- neprilysin inhibitors, V ascular Health and Risk Management 2015:11 283–295.Akshay S. Desai et al, Influence of Sacubitril Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization, JACC VOL. 68, NO.3, 2016, JULY 19, 2016: 241–8.Dargad RR, Prajapati MR, Dargad RR, Parekh JD. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.Indian Heart J. 2018; 70 Suppl 1(Suppl 1): S102-S110.Ganesananthan S, Shah N, Shah P, et al. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study. Open Heart. 2020; 7(2): e001305.Writing Committee, Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, et al. 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021 Jan 4: S0735-1097 (20) 37867-0.Wachter R, Senni M, Belohlavek J, et al. TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail. 2019 Aug; 21(8): 998-1007.Senni M, McMurray JJ, Wachter R, et al. Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens. Eur J Heart Fail. 2016 Sep; 18(9): 1193-202.Deiby Boneu Yepez, Robinson Barragán Montiel, Dayana Arroyo Carrascal - 2021https://creativecommons.org/licenses/by-nc-sa/4.0http://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessEsta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3500Heart failureValsartanNeprilysinAtrial natriuretic factorAngiotensin-converting enzyme inhibitorsInsuficiencia CardíacaValsartánNeprilisinaPéptido natriurético atrialInhibidores de la enzima convertidora de angiotensinaAsociación entre valsartán e inhibidores de neprilisina en el manejo de la falla cardiaca.Association between valsartan and neprilisin inhibitors in the management of heart failure.Artículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_dcae04bchttp://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articleJournal articlehttp://purl.org/redcol/resource_type/ARTREVPublicationOREORE.xmltext/xml2679https://repositorio.unicartagena.edu.co/bitstreams/3793f95a-21ff-4137-8fb5-f21daef45a5a/downloadd57484b0c8f732abff7b01919e4ce92aMD5111227/13491oai:repositorio.unicartagena.edu.co:11227/134912024-09-05 15:30:24.889https://creativecommons.org/licenses/by-nc-sa/4.0Deiby Boneu Yepez, Robinson Barragán Montiel, Dayana Arroyo Carrascal - 2021metadata.onlyhttps://repositorio.unicartagena.edu.coBiblioteca Digital Universidad de Cartagenabdigital@metabiblioteca.com

Asociación entre valsartán e inhibidores de neprilisina en el manejo de la falla cardiaca.

Publicaciones similares